I
3.28
0.73 (28.63%)
| Previous Close | 2.55 |
| Open | 2.50 |
| Volume | 1,181,608 |
| Avg. Volume (3M) | 92,238 |
| Market Cap | 105,510,968 |
| Price / Sales | 17.44 |
| Price / Book | 196.27 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Operating Margin (TTM) | -273.01% |
| Diluted EPS (TTM) | -3.79 |
| Quarterly Revenue Growth (YOY) | 1,114.80% |
| Total Debt/Equity (MRQ) | 34.04% |
| Current Ratio (MRQ) | 3.74 |
| Operating Cash Flow (TTM) | -22.74 M |
| Levered Free Cash Flow (TTM) | -15.27 M |
| Return on Assets (TTM) | -22.17% |
| Return on Equity (TTM) | -428.96% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | Insight Molecular Diagnostics I | Bullish | - |
AIStockmoo Score
-0.6
| Analyst Consensus | 3.5 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.60 |
|
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 22.47% |
| % Held by Institutions | 56.26% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Broadwood Capital Inc | 31 Dec 2025 | 11,410,100 |
| 52 Weeks Range | ||
| Median | 12.00 (265.85%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Lake Street | 17 Feb 2026 | 12.00 (265.85%) | Buy | 5.39 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JAMES ANDREA S. | - | 4.11 | -11,298 | -46,435 |
| LIU JAMES YANG | - | 4.11 | -2,578 | -10,596 |
| RIGGS JOSH | - | 4.11 | -12,310 | -50,594 |
| Aggregate Net Quantity | -26,186 | |||
| Aggregate Net Value ($) | -107,624 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 4.11 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LIU JAMES YANG | Officer | 26 Mar 2026 | Disposed (-) | 2,578 | 4.11 | 10,596 |
| LIU JAMES YANG | Officer | 26 Mar 2026 | Option execute | 6,289 | - | - |
| RIGGS JOSH | Officer | 26 Mar 2026 | Disposed (-) | 12,310 | 4.11 | 50,594 |
| RIGGS JOSH | Officer | 26 Mar 2026 | Option execute | 47,170 | - | - |
| JAMES ANDREA S. | Officer | 26 Mar 2026 | Disposed (-) | 11,298 | 4.11 | 46,435 |
| JAMES ANDREA S. | Officer | 26 Mar 2026 | Option execute | 28,302 | - | - |
| Date | Type | Details |
|---|---|---|
| 13 Jan 2026 | Announcement | IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring |
| 07 Jan 2026 | Announcement | iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation |
| 06 Jan 2026 | Announcement | iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch |
| 05 Jan 2026 | Announcement | iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |